Health Care Innovation
Commentary
In coronavirus battle, price controls would make it harder to develop lifesaving drugs
As scientists race to develop vaccines and treatments for COVID-19, Democrats in Congress have renewed their push for price controls on drugs designed to protect us from the respiratory disease caused by the coronavirus, along with other illnesses. The Democrats claim many Americans will only be able to afford the therapies that ...
Blog
Single Payer Poll Watch: Coronavirus Update
Coronavirus is impacting everything and anything it touches. In the March PRI Single Payer Poll Watch, average opposition to a single payer plan overtook support, continuing the trend of growing opposition to a single payer health care plan PRI noticed in our first poll watch in December 2019. With the ...
Commentary
As Coronavirus Spreads, Private Sector Offers Hope—And Treatments
Optimism is in short supply as the coronavirus pandemic grows deadlier by the day. COVID-19 has taken thousands of lives around the world and upended nearly every aspect of daily life. But there is at least one bright spot in this global public health emergency. That’s the astounding speed with ...
Drug Importation
New Animated Series Aims to Help Patients “Escape the Drug Pricing Maze”
SAN FRANCISCO – As prescription drug pricing and accessibility has become a greater topic of discussion during the current coronavirus pandemic, a new series of animated videos launched today by the Center for Medical Economics and Innovation at the Pacific Research Institute aims to guide Americans through the “drug pricing ...
Commentary
Coronavirus shows why you don’t want price controls during a pandemic
The World Health Organization has declared the novel coronavirus a global pandemic, with more than 118,000 confirmed cases worldwide. As countries brace for the worst, people around the world are looking to the United States for a drug that can prevent or cure the disease. The world is right to put its ...
Featured
NEW ISSUE BRIEF: Expanding Biosimilars Use Could Save Patients, Reduce Out-of-Pocket Costs By 17 Percent
Expanding the use of biosimilars to treat serious illnesses like cancer or auto-immune diseases could reduce a patient’s out-of-pocket costs by 17 percent, finds a new issue brief released today by the Center for Medical Economics and Innovation at the Pacific Research Institute. Click here to download the study “Biologics ...
Commentary
Coronavirus Just the Latest Example of U.N. Incompetence and Failure
The World Health Organization, a part of the United Nations, has proposed an official name, COVID-19, for the illness caused by the Wuhan coronavirus, after the city in China where it emerged. (The new designation stands for coronavirus disease 2019, as the illness was first detected toward the end of ...
Commentary
Bernie’s Math Problem
Anyone in earshot of a television set, or a smart phone, is undoubtedly aware that the undisputed front-runner in the Democratic Primary wants to spend more money – a lot of it. And, while these policies are economically flawed, Senator Sanders also has a fundamental math problem. Reviewing his website, there ...
Commentary
Just say no to California’s drug-making plan
California wants to get into the drug making business. Gov. Gavin Newsom just announced his intention to have the state contract with generic drug manufacturers to make drugs to sell to state residents, presumably at lower cost than they’re available on the market today. But the plan won’t deliver much ...
Commentary
Pelosi’s Drug Price Controls Are Dangerous—But So Are Trump’s
The White House Council of Economic Advisors just issued a damning indictment of a House bill (H.R. 3) designed to lower drug prices. According to White House economists, the measure endorsed by Nancy Pelosi and her fellow House Democrats could prevent the development of 100 new drugs over the next ten years. ...
In coronavirus battle, price controls would make it harder to develop lifesaving drugs
As scientists race to develop vaccines and treatments for COVID-19, Democrats in Congress have renewed their push for price controls on drugs designed to protect us from the respiratory disease caused by the coronavirus, along with other illnesses. The Democrats claim many Americans will only be able to afford the therapies that ...
Single Payer Poll Watch: Coronavirus Update
Coronavirus is impacting everything and anything it touches. In the March PRI Single Payer Poll Watch, average opposition to a single payer plan overtook support, continuing the trend of growing opposition to a single payer health care plan PRI noticed in our first poll watch in December 2019. With the ...
As Coronavirus Spreads, Private Sector Offers Hope—And Treatments
Optimism is in short supply as the coronavirus pandemic grows deadlier by the day. COVID-19 has taken thousands of lives around the world and upended nearly every aspect of daily life. But there is at least one bright spot in this global public health emergency. That’s the astounding speed with ...
New Animated Series Aims to Help Patients “Escape the Drug Pricing Maze”
SAN FRANCISCO – As prescription drug pricing and accessibility has become a greater topic of discussion during the current coronavirus pandemic, a new series of animated videos launched today by the Center for Medical Economics and Innovation at the Pacific Research Institute aims to guide Americans through the “drug pricing ...
Coronavirus shows why you don’t want price controls during a pandemic
The World Health Organization has declared the novel coronavirus a global pandemic, with more than 118,000 confirmed cases worldwide. As countries brace for the worst, people around the world are looking to the United States for a drug that can prevent or cure the disease. The world is right to put its ...
NEW ISSUE BRIEF: Expanding Biosimilars Use Could Save Patients, Reduce Out-of-Pocket Costs By 17 Percent
Expanding the use of biosimilars to treat serious illnesses like cancer or auto-immune diseases could reduce a patient’s out-of-pocket costs by 17 percent, finds a new issue brief released today by the Center for Medical Economics and Innovation at the Pacific Research Institute. Click here to download the study “Biologics ...
Coronavirus Just the Latest Example of U.N. Incompetence and Failure
The World Health Organization, a part of the United Nations, has proposed an official name, COVID-19, for the illness caused by the Wuhan coronavirus, after the city in China where it emerged. (The new designation stands for coronavirus disease 2019, as the illness was first detected toward the end of ...
Bernie’s Math Problem
Anyone in earshot of a television set, or a smart phone, is undoubtedly aware that the undisputed front-runner in the Democratic Primary wants to spend more money – a lot of it. And, while these policies are economically flawed, Senator Sanders also has a fundamental math problem. Reviewing his website, there ...
Just say no to California’s drug-making plan
California wants to get into the drug making business. Gov. Gavin Newsom just announced his intention to have the state contract with generic drug manufacturers to make drugs to sell to state residents, presumably at lower cost than they’re available on the market today. But the plan won’t deliver much ...
Pelosi’s Drug Price Controls Are Dangerous—But So Are Trump’s
The White House Council of Economic Advisors just issued a damning indictment of a House bill (H.R. 3) designed to lower drug prices. According to White House economists, the measure endorsed by Nancy Pelosi and her fellow House Democrats could prevent the development of 100 new drugs over the next ten years. ...
